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Abstract
Background Hyperphosphatemia is common in chronic
kidney disease (CKD) and associated with mortality and
morbidity. We aimed to evaluate the dose-dependent effi-
cacy and safety of PA21 (sucroferric oxyhydroxide), an
iron-based phosphate binder, in Japanese hemodialysis
patients with hyperphosphatemia.
Methods In this double-blind, multicenter, Phase II study,
183 patients were randomized to placebo or PA21 at doses
of 250, 500, 750, or 1000 mg (based on iron content) three
times/day for 6 weeks. The primary efficacy endpoint was
the mean change in serum phosphorus levels from baseline
to end of treatment in each group. Adverse reactions were
evaluated.
Results The change in serum phosphorus level was sig-
nificantly greater in each PA21 group than in the placebo
group (analysis of covariance: P\ 0.001 for all groups). A
dose-dependent change in serum phosphorus levels was
observed in the PA21 groups. A notable decrease in mean
serum phosphorus levels to the target level of B6 mg/dL
was shown starting at Week 1 in all PA21 groups. The
cumulative achievement rates for target serum phosphorus
level at the end of treatment were generally[80 % in all
PA21 groups. The major adverse reaction reported was
diarrhea; however, most cases were mild.
Conclusions PA21 was an effective and safe treatment that
decreased serum phosphorus levels starting at 1 week of
treatment when administered as one 250-mg tablet three
times/day. PA21 demonstrated a dose-dependent phospho-
rus lowering effect up to 3000 mg/day. PA21 may be a new
treatment alternative with relatively low pill burden for
Japanese hemodialysis patients with hyperphosphatemia.
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Introduction
Dietary phosphate is absorbed from the gastrointestinal
tract and excreted mainly through the kidneys. Eventually,
hyperphosphatemia occurs in end-stage renal disease, as a
result of phosphorus accumulation in the body. Addition-
ally, bone mineral (e.g., calcium and phosphorus) meta-
bolism abnormalities associated with chronic kidney
disease (CKD) are designated as CKD-mineral and bone
disorder, which is a systemic disease that influences the
prognosis by affecting not only bones but also blood ves-
sels and accelerating medial arterial calcification and
arteriosclerosis [1, 2]. It is known that hyperphosphatemia
causes and/or worsens ectopic calcification and secondary
hyperparathyroidism. Furthermore, increased serum phos-
phorus levels have been reported to be an independent
prognostic factor for mortality [3, 4]. Therefore, manage-
ment of serum phosphorus in chronic hemodialysis patients
is recommended in CKD management guidelines in many
countries including Japan [1, 5, 6]. Although dietary ther-
apy is the basic treatment for patients with CKD, and a
certain amount of phosphorus can be eliminated by
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hemodialysis, excessive protein restriction causes malnu-
trition and may increase the risk of death [7], and con-
ventional hemodialysis cannot completely eliminate
phosphorus excess. Thus, in addition to dietary therapy and
hemodialysis, oral phosphate binders are needed to inhibit
the absorption of dietary phosphate and prevent vascular
calcifications in CKD patients [8, 9].
The use of sevelamer hydrochloride, lanthanum car-
bonate, and bixalomer was approved in the 2000s in
Japan, in addition to conventional calcium carbonate, to
prevent the excessive phosphorus absorption in chronic
hemodialysis patients. Ferric citrate was introduced in
2014. Although calcium carbonate is widely used for its
effectiveness, some concerns have been raised regarding
hypercalcemia and vascular calcification, which are
caused by the uptake of calcium contained in the drug
[10, 11]. Sevelamer hydrochloride and bixalomer, both of
which are non-absorbed polymers containing no calcium,
do not raise concerns related to calcium absorption.
However, in Japan, sevelamer hydrochloride is only
available in the form of 250-mg tablets, and patients are
required to take at least three or four tablets/dose to
control their serum phosphorus levels in clinical practice.
Furthermore, a high incidence of gastrointestinal adverse
reactions has been reported in patients treated with these
drugs, such as abdominal distension and constipation [12].
Regarding lanthanum carbonate, its effect can be obtained
with a smaller number of tablets, but it causes a high
incidence (approximately 10 %) of vomiting and nausea
[13]. Some concerns have been raised about the absorp-
tion and its effects on the long-term safety of lanthanum,
which is a rare metal. Moreover, regarding the use of
ferric citrate, there is concern about the elevation of
serum ferritin levels [14].
PA21, a mixture of polynuclear iron (III) oxyhydroxide,
sucrose, and starches, is a novel non-calcium-based phos-
phate binder [15]. An in vitro study showed that the
phosphate binding capacity of PA21 was over a physio-
logically relevant pH range in the gastrointestinal tract
[16]. In a Phase III study conducted in multiple sites across
Europe, the United States, Russia, Ukraine, and South
Africa, the phosphorus-lowering effect of PA21 was shown
by demonstrating its non-inferiority to sevelamer carbonate
and superiority to an ineffective control [17]. An extension
of the Phase III study confirmed the long-term efficacy of
PA21 which was maintained over 1 year [18]. Addition-
ally, PA21 has been launched in Europe and the United
States, among other regions and countries. The present
study aimed to evaluate the dose-dependent efficacy and




The inclusion criteria were as follows: men and women
C20 years of age at the time consent was obtained who
were considered able to discontinue their current hyper-
phosphatemia therapy for the 3-week wash-out period;
subjects who, before the wash-out period, were undergoing
maintenance hemodialysis three times weekly for
C12 weeks and planned to continue hemodialysis during
the study treatment period, did not undergo changes in the
dose of phosphate binder agent, vitamin D receptor acti-
vator or vitamin D receptor modulator, calcium sensing
receptor agonist of calcimimetics, or anti-osteoporotic
agents for C4 weeks, or did not present changes in the
dialysate calcium concentration for C4 weeks; and those
with serum phosphorus concentration[6.0 and B10 mg/dL
at the first dialysis session in the wash-out period (Week-1).
The main exclusion criteria were as follows: subjects
who, before the first dialysis session of the wash-out per-
iod, had a corrected serum calcium concentration B7.5 or
[11.0 mg/dL, an intact parathyroid hormone (PTH) con-
centration of[800 pg/mL, or a concentration[500 pg/mL
if determined to have poor control; history of hemochro-
matosis, any other iron overload disorder, serum ferritin
[800 ng/mL, or transferrin saturation [50 %; subjects
planning to undergo parathyroidectomy or percutaneous
ethanol injection therapy (PEIT) during the study period, or
who underwent parathyroidectomy or PEIT B24 weeks
before their wash-out period; clinically significant gas-
trointestinal disorder or history of a clinically significant
digestive tract procedure according to the investigator’s
diagnosis; clinically significant hepatic disorder (e.g., ala-
nine transaminase or aspartate transaminase C100 U/L or
total bilirubin C3.0 mg/dL); and history of brain/cardio-
vascular disorder (e.g., myocardial infarct, unstable angina,
cerebral infarct, cerebral hemorrhage). Other phosphate
binders, agents with a phosphorus adsorption effect, agents
that affect serum phosphorus levels, and intravenous and
oral iron therapies were not permitted. Patients were
withdrawn if their serum phosphorus levels exceeded
10 mg/dL or decreased below 3.0 mg/dL during two con-
secutive evaluations, or if their corrected serum calcium
levels decreased below 7.5 mg/dL.
The present study was approved by the institutional
review board of each participating center (approval num-
ber: PA1201) and performed in accordance with the Hel-
sinki Declaration of 1964, as revised in 2000. Written
informed consent was obtained from all individual partic-
ipants included in the study.
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Study design and treatment
This Phase II, randomized, placebo-controlled, double-
blind comparative study included hemodialysis patients
from 14 centers in Japan. The present study had a 3-week
wash-out period and a 6-week treatment period in which
placebo or PA21 doses of 250, 500, 750, or 1000 mg were
orally administered three times/day prior to meals. The
subjects were randomized to the following five groups:
750-, 1500-, 2250-, 3000-mg/day, and placebo group. Each
PA21 tablet contained 250 mg of iron. The placebo tablet
did not contain active moiety. Randomization of subjects
was carried out by interactive web response system with
subjects randomized in a 1:1:1:1:1 ratio to one of the four
PA21 groups or the placebo group. The trial was registered
on ClinicalTrials.gov (NCT01521494).
Efficacy endpoints
The primary efficacy endpoint was the mean change in
serum phosphorus levels from baseline to end of treatment
in each treatment group. Additional evaluations of the
primary endpoint included serum phosphorus level at each
time-point and cumulative achievement rates for target
serum phosphorus level defined as the proportion of
patients with serum phosphorus level of B6 mg/dL at each
time-point according to the upper limit of the target range
of the Japanese Society for Dialysis Therapy (JSDT)
guidelines [6]. The secondary efficacy endpoints were
corrected serum calcium levels and serum intact-PTH
levels.
Safety and tolerability
Safety outcomes included adverse events (AEs), adverse
drug reactions (ADRs), laboratory tests (including ferritin,
transferrin saturation, and hemoglobin level), physical
examination (e.g., vital signs), and 12-lead electrocardio-
graphy (ECG) findings.
Statistical analysis
The planned sample size was 150 subjects (30 per group) to
have a 90 % power to detect a 1.6 mg/dL difference in
serum phosphorus level between the PA21 and placebo
groups. This calculation assumed a standard deviation of
1.8 mg/dL using an alpha level of 0.05. The primary effi-
cacy endpoint and serum phosphorus concentration at each
time-point were summarized by dose group using
descriptive statistics. The primary endpoint was compared
between the treatment and placebo groups using analysis of
covariance (ANCOVA) with baseline serum phosphorus
levels as covariates. For the primary efficacy endpoint, a
closed testing procedure was used to allow multiple sta-
tistical comparisons between each PA21 group and the
placebo group while maintaining the Type I error rate at
0.05. Cumulative achievement rates for target serum
phosphorus levels were calculated per group at each eval-
uation time. Comparisons between the placebo group and
each PA21 group were made using Fisher’s exact test.
Descriptive statistics were used for each secondary end-
point measure by group at each evaluation time. The
number and incidences of AEs and ADRs were calculated
in each group. The AEs and ADRs did not include dis-
coloration events caused by the iron contained in PA21 and
were classified according to (MedDRA) primary System
Organ Class and Preferred Terms. Statistical significance
was set at P\ 0.05. All statistical analyses were performed
using SAS 9.3 Foundation for Microsoft Windows (SAS
Institute Inc., Cary, NC, USA).
Results
Subjects
A total of 313 patients were screened in this study, and
eligible 183 subjects were randomized to the placebo and
PA21 groups. The disposition of patients is shown in
Fig. 1. A total of 178 and 183 subjects were included in the
full analysis set and safety analysis set, respectively. Of the
183 patients randomized, the proportion of subjects who
discontinued treatment was 18.9 % (7/37) in the placebo
group and 5.1 % (2/39), 13.9 % (5/36), 34.3 % (12/35),
and 58.3 % (21/36) in the 750-, 1500,- 2250-, and 3000-mg
PA21 groups, respectively. The reasons for discontinuation
in each treatment group are shown in Fig. 1. Seventeen
patients discontinued treatment because their serum phos-
phorus levels decreased to below the defined criterion for
discontinuation. Among them, 15 patients received higher
doses of PA21 (three patients in the 2250-mg group and 12
patients in the 3000-mg group). Eleven patients discon-
tinued treatment because of diarrhea. Of these, nine
patients received higher doses of PA21 (five patients in the
2250-mg group and four patients in the 3000-mg group). In
all the patients, the diarrhea was resolved with discontin-
uation of the investigational product. In total, 136 patients
completed the study (106 in the PA21 groups and 30 in the
placebo group).
The background characteristics of patients are shown in
Table 1. The five groups were generally comparable.
Among the 178 subjects analyzed (full analysis set), the
mean ± standard deviation age was 61.4 ± 10.9 years and
115 were men (64.6 %).
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Primary efficacy outcome and additional evaluations
The mean changes in serum phosphorus levels from
baseline to end of treatment (adjusted for serum phospho-
rus levels at baseline) are shown in Fig. 2. The change in
serum phosphorus level in each PA21 group was signifi-
cantly greater than that in the placebo group (ANCOVA
with serum phosphorus levels at baseline as covariates:
P\ 0.001 for all groups). A dose-dependent change in
serum phosphorus levels in the PA21 groups was observed.
Good compliance to treatment with the study drug was
seen throughout the treatment; moreover, there were no
changes in the protein catabolic rate and Kt/V (K, clear-
ance; t, dialysis time; V, urea distribution volume) from
baseline to end of treatment (Table 2).
The time course of mean serum phosphorus levels in the
full analysis set is shown in Fig. 3. A notable decrease in
mean serum phosphorus levels to the target serum phos-
phorus level of B6 mg/dL was shown as early as Week 1 in
all PA21 groups. This decreasing tendency was maintained
until Week 6 (end of treatment).
The cumulative achievement rates for target serum
phosphorus level (B6 mg/dL) at each time-point are shown
in Fig. 4. The cumulative achievement rates were signifi-
cantly higher in all the PA21 groups than in the placebo
group (all P\ 0.001, Fisher’s exact test).
Secondary efficacy outcomes
No significant changes were observed in the corrected
serum calcium levels. Although the intact-PTH levels
increased from Week-3 to Week 0 (baseline) because of the
wash-out of the phosphate binder, the levels at the end of
treatment decreased to those measured at the wash-out
period (Table 2).
Safety and tolerability
The incidence of AEs was 54.1 % (20/37) in the placebo
group and 61.5 % (24/39), 44.4 % (16/36), 77.1 % (27/35),
and 72.2 % (26/36) in the 750-, 1500-, 2250-, and 3000-mg
PA21 groups, respectively. The incidence of ADRs was
10.8 % (4/37) in the placebo group and 23.1 % (9/39),
13.9 % (5/36), 40.0 % (14/35), and 44.4 (16/36) in the
750-, 1500-, 2250-, and 3000-mg PA21 groups, respec-
tively. The most frequently reported AEs and ADRs (in-
cidence C5 % in any PA21 group) are shown in Table 3.
Diarrhea was reported more frequently in the PA21 groups.
However, most cases were mild, and more than half of the
cases occurred within 2 days after dose initiation. The time
to onset of diarrhea is shown in Table 4.
Regarding the severity of ADRs, there were five
mild reports in the placebo group, and 44 mild and eight
Fig. 1 Disposition of patients. Some subjects had more than one reason for discontinuation. Abbreviations Ca calcium, P phosphorus
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moderate reports in the PA21 groups, with no severe events
being noted. The moderate AEs broke down into five
reports of diarrhea (one report in the PA21 1500-mg group,
and two reports each in the 2250- and 3000-mg groups),
one of abdominal distension (in the 3000-mg group), one of
epigastric discomfort (in the 3000-mg group), and one of
reduced visual acuity (in the 750-mg group).
During the treatment period, there were a total of eight
serious AEs in seven patients in the placebo and PA21
groups. However, all these events were assessed as not
related to the investigational product. No deaths were noted
in the treatment period.
In ferritin, transferrin saturation, and hemoglobin levels,
slight increases were seen in the PA21 groups (Table 5).
In physical examination and 12-lead ECG, no clinically
significant changes and no abnormal findings were
observed, respectively, in any treatment group.
Discussion
This is the first randomized, placebo-controlled, double-
blind comparative study of PA21 in Japanese hemodialysis
patients.
Fig. 2 Change from baseline to end of treatment in serum phospho-
rus levels (full analysis set). The changes in serum phosphorus levels
from baseline to end of treatment are adjusted for serum phosphorus
levels at baseline. ANCOVA: * P\ 0.001 for all PA21 groups vs
placebo


















Men 115 (64.6) 27 (69.2) 23 (65.7) 23 (69.7) 19 (55.9) 23 (62.2)
Women 63 (35.4) 12 (30.8) 12 (34.3) 10 (30.3) 15 (44.1) 14 (37.8)
Age (years) 61.4 ± 10.9 59.4 ± 10.4 63.8 ± 12.0 61.9 ± 10.5 61.4 ± 11.2 60.8 ± 10.2
Primary disease (n)
Diabetic nephropathy 52 14 9 5 10 14
Chronic glomerulonephritis 56 12 8 11 14 11
Nephrosclerosis 23 7 6 6 1 3
Polycystic kidney disease 10 2 2 2 1 3
Chronic pyelonephritis 1 0 0 1 0 0
Others 11 0 2 3 3 3
Unknown 26 4 8 6 5 3
Mode of dialysis
Hemodialysis 176 (98.9) 38 (97.4) 35 (100.0) 32 (97.0) 34 (100.0) 37 (100.0)
Hemodiafiltration 2 (1.1) 1 (2.6) 0 (0) 1 (3.0) 0 (0) 0 (0)
Dialysis vintage (months) 83.7 ± 63.5 77.6 ± 67.5 85.1 ± 60.7 95.8 ± 81.9 91.5 ± 58.6 71.0 ± 45.0
Serum phosphorus (mg/dL) 7.46 ± 1.22 7.36 ± 1.18 7.69 ± 1.32 7.42 ± 0.87 7.57 ± 1.33 7.26 ± 1.35
Corrected serum calcium
(mg/dL)
8.60 ± 0.56 8.49 ± 0.46 8.65 ± 0.52 8.59 ± 0.66 8.69 ± 0.52 8.58 ± 0.61
Intact parathyroid hormone
(pg/mL)
285.3 ± 151.1 277.9 ± 148.9 262.1 ± 139.7 345.0 ± 176.1 262.8 ± 143.3 282.4 ± 140.5
Data are presented as n (%) or mean ± SD, unless otherwise stated
Fisher’s exact text was used to determine differences in sex. One-way analysis of variance was used to determine differences in age and serum
phosphorus, calcium, and intact parathyroid hormone levels between the groups
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In the present study, the change (mean change adjusted
for baseline serum phosphorus level) in serum phosphorus
levels from baseline to the end of treatment in all the PA21
groups was significantly different from that in the placebo
group. Furthermore, PA21 in the dose range of
750–3000 mg/day decreased serum phosphorus levels in a
clear dose-responsive manner.
With PA21 given at 750 mg/day, the mean serum
phosphorus level decreased to B6 mg/dL from Week 1 of
treatment, which is the upper limit of the management
target range recommended by the JSDT guidelines [6].
Other phosphate binders administered in minimal doses
could not lower serum phosphorus to levels lower than
6 mg/dL from Week 1 [19–21]. With PA21 given at a dose
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of 1500 mg/day and more, the mean serum phosphorus
level decreased to B5.5 mg/dL from Week 1 of treatment,
which is the upper limit of the management target range
recommended by the Kidney Disease Outcomes Quality
Initiative guidelines [1].
The efficacy of PA21 was previously confirmed in a
Phase II study conducted at multiple sites across Europe and
the United States, in which PA21 at dosages of
1000–2500 mg/day was found to be effective in reducing
serum phosphorus levels in patients with hyperphos-
phatemia undergoing hemodialysis [22]. Although both the
current study and the previous study showed a dose-re-
sponsive serum phosphorus-lowering effect, the efficacy of
PA21 was evaluated by comparison with the placebo in the
current study, but by comparison with the baseline serum
phosphorus concentration in the previous study. Further-
more, a significant serum phosphorus-lowering effect was
seen with PA21 at a dose of 750 mg/day or higher in the
current study. Efficacy was confirmed at a lower dose in the
current study than in the previous study, in which the lowest
effective dose was 5.0 g/day, which is equal to
1000 mg/day with iron. In all of the PA21 groups, a sig-
nificant difference from the placebo group was observed in
the cumulative achievement rate of the serum phosphorus
level (B6 mg/dL) at the end of treatment.
These results show that PA21 at a dose of one 250-mg
tablet three times/day decreases serum phosphorus levels
from the first week of treatment. Furthermore, PA21
demonstrated a dose-dependent phosphorus lowering effect
up to 3000 mg/day. The number of patients who discon-
tinued the treatment because their serum phosphorus con-
centration decreased to below the defined criterion for
discontinuation was especially high in the high-dose (2250
and 3000 mg/day) groups. This indicates that PA21 is very
effective at lowering serum phosphorus levels.
A lower pill burden is associated with a higher adher-
ence, and furthermore, with a good control of phosphorus
levels [23]. Hence, PA21, which shows a serum phospho-
rus-lowering effect with a single 250-mg tablet/dose, is
expected to reduce pill burden and may provide a clinically
relevant benefit for serum phosphorus management in
dialysis patients.
In both the placebo and PA21 groups, corrected serum
calcium levels decreased from Week-3 to baseline, and
thereafter, returned to the levels observed at Week-3 in the
PA21 groups. Conversely, serum intact-PTH levels
increased from Week-3 to baseline, and decreased, there-
after, in the PA21 groups.
PA21 was suggested to secondarily control serum intact-
PTH levels by decreasing serum phosphorus levels, with-
out affecting corrected serum calcium levels. The similar
intact-PTH changes, which are considered a secondary
change related to serum phosphorus levels, were shown for
other non-calcium phosphate binders [19–21].
ADRs that occurred at an incidence of C5 % in any of
the PA 21 groups were diarrhea and constipation, both of
which were classified as gastrointestinal disorders. Most
cases of diarrhea were mild, and more than half of these
cases occurred within 2 days after the initial dose. The
severity of the ADRs was mild to moderate, and there were
no severe events. The incidence of treatment discontinua-
tion was higher in the high-dose groups. This may be
because no dose reduction was possible even in the event
of diarrhea, and because higher doses (2250 and
Fig. 3 Time course of mean serum phosphorus levels (full analysis
set). The mean serum phosphorus levels were significantly higher in
all the PA21 groups in all the time-points after administering the
PA21 dose (all P\ 0.001, one-sample t test)
Fig. 4 Cumulative achievement rates of target serum phosphorus
levels (B6.0 mg/dL) (full analysis set). The numbers of patients
analyzed in the 750-, 1500-, 2250-, 3000-mg, and placebo group were
36, 32, 32, 29, and 31, respectively. The cumulative achievement
rates were significantly higher in all the PA21 groups than in the
placebo group (all * P\ 0.001, Fisher’s exact test)
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3000 mg/day) were administered from the study start.
Although diarrhea occurred frequently in high-dose groups,
the incidence of diarrhea was similar between the low-dose
(750 and 1500 mg/day) and placebo groups. We consider
that the number of cases of excessive phosphorus decrease
can be reduced or the development of diarrhea can be
avoided by starting treatment at a minimum dose of
750 mg/day.
In laboratory tests, serum ferritin, transferrin saturation,
and hemoglobin values tended to increase slightly in the
PA21 groups and without a dose-dependent trend. In a
clinical pharmacological study evaluating the absorption of
iron from PA21 given at a dose of 2000 mg/day, iron
absorption after administration of PA21 was very low [24].
Therefore, it is unlikely that iron-related parameters would
increase excessively after administration of PA21.
The present study has some limitations. This study only
included Japanese patients; thus, the generalizability of the
results is limited. However, although the findings of the
present study are applicable only to the Japanese popula-
tion, previous randomized controlled trials have shown a
similar serum phosphorus-decreasing effect and safety
profile in other ethnic populations [17, 22]. Another limi-
tation is that the placebo did not contain iron; therefore, the
participants or the investigators might have discriminated
the study drug from the placebo by the stool color. Other
limiting factors were the relatively short study duration and
the use of placebo as a comparator. Further long-term
studies comparing PA21 with other standard therapy in
Japanese patients are warranted.
Conclusion
This study showed that, in the Japanese population, PA21
is an effective and safe phosphate binder that decreases
serum phosphorus levels starting at 1 week of treatment
when administered at a dose of one 250-mg tablet three
times/day. Furthermore, PA21 demonstrated a dose-de-

















Diarrhea 6 (15.4) 6 (16.7) 13 (37.1) 15 (41.7) 7 (18.9)
Contusion 0 (0.0) 0 (0.0) 0 (0.0) 4 (11.1) 0 (0.0)
Nasopharyngitis 5 (12.8) 5 (13.9) 3 (8.6) 3 (8.3) 4 (10.8)
Constipation 0 (0.0) 1 (2.8) 2 (5.7) 2 (5.6) 1 (2.7)
Abdominal pain 0 (0.0) 0 (0.0) 0 (0.0) 2 (5.6) 0 (0.0)
Pain in extremity 0 (0.0) 1 (2.8) 2 (5.7) 0 (0.0) 0 (0.0)
Hemorrhoids 0 (0.0) 0 (0.0) 2 (5.7) 0 (0.0) 0 (0.0)
Insomnia 2 (5.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Upper respiratory tract
inflammation
2 (5.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Adverse drug reactions
Diarrhea 4 (10.3) 4 (11.1) 12 (34.3) 12 (33.3) 3 (8.1)
Constipation 0 (0.0) 1 (2.8) 2 (5.7) 1 (2.8) 0 (0.0)
Data are presented as n (%)
Table 4 Time to onset of diarrhea
Time to onset PA21 groups Placebo group
1–7 days 31 4
1st day 6 0
2nd day 10 1
3rd day 8 1
4th day 2 0
5th day 5 1
6th day 0 1
7th day 0 0
8–14 days 3 0
15–21 days 2 2
22–28 days 2 0
29–35 days 0 0
36–42 days 2 1
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pendent phosphorus lowering effect up to 3000 mg/day.
Therefore, PA21 is useful as a new treatment alternative
with a relatively low pill burden for Japanese hemodialysis
patients with hyperphosphatemia.
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